CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

RGENREPLIGEN CORP

NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Last close $192.23 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Market cap$10.85B
CountryUSA
RECENT INSIDER TRADES
  • 2026-10-08 · Douglass Brian Robb (CHIEF PRODUCT OFFICER) · OTHER
  • 2026-10-06 · Loeillot Olivier (Chief Executive Officer) · OTHER
  • 2026-10-06 · Loeillot Olivier (Chief Executive Officer) · SELL
  • 2026-10-05 · Loeillot Olivier (Chief Executive Officer) · OTHER
INSTITUTIONAL OWNERSHIP
Institutional holders524
Shares held79,996,287
Value$10.40B
Percent of shares outstanding141.75%
As of quarter end2026-06-30
RECENT NEWS
  • Repligen to acquire BioLife Solutions
  • Repligen stock price target reaffirmed at $225 by UBS on growth outlook
  • Repligen CEO Olivier Loeillot sells $976,680 in company stock
  • Repligen CEO Loeillot sells $2.46m in shares
  • REPLIGEN CORP · 8-K (8.01)
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS
REPLIGEN CORP (RGEN) · Stock Price, Insider Trades, Institutional Holdings · CatalystPit